Assessment of serum endocan levels in patients with beta-thalassemia minor

Detalhes bibliográficos
Autor(a) principal: Khanmammadov,Nijat
Data de Publicação: 2022
Outros Autores: Zorlu,Mehmet, Ozer,Omer Faruk, Karatoprak,Cumali, Kıskaç,Muharrem, Çakırca,Mustafa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Associação Médica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000200147
Resumo: SUMMARY OBJECTIVE: Beta-thalassemia minor is a blood disease caused by a hereditary decrease in beta-globin synthesis, frequently leading to hypochromic microcytic anemia. Formerly called endothelial cell-specific molecule 1, endocan is a proteoglycan released by vascular endothelial cells in many organs. Our aim was to investigate the relationship between the beta-thalassemia minor patients and the healthy control group in terms of serum endocan level. METHODS: The study was performed in a total of 80 subjects. They were divided into two groups, the beta-thalassemia minor group (n=40) and the healthy control group (n=40). Serum endocan levels, age, sex, body mass index value, and tobacco use data of these groups were compared. RESULTS: No statistically significant difference was detected between the two groups in terms of age, sex, and body mass index values (p>0.05). Endocan levels were measured to be 206.85±88.1 pg/mL in the beta-thalassemia minor group and 236.1±162.8 pg/mL in the control group with no significant difference between the groups in terms of serum endocan levels (p>0.05). CONCLUSIONS: In our study, there was no change in endocan level in beta-thalassemia minor. This might be because serum endocan levels are affected by multi-factorial reasons. Serum endocan levels may be altered secondarily to decreased beta-globin chain, increased sympathetic activity due to anemia, or platelet dysfunction induced by oxidative stress in beta-thalassemia minor. Further multicenter studies involving more patients are necessary to demonstrate this.
id AMB-1_898ea7a1d93f9326032aeb2c4dceb692
oai_identifier_str oai:scielo:S0104-42302022000200147
network_acronym_str AMB-1
network_name_str Revista da Associação Médica Brasileira (Online)
repository_id_str
spelling Assessment of serum endocan levels in patients with beta-thalassemia minorThalassemiaAnemiaEndothelial cellsProteoglycanSUMMARY OBJECTIVE: Beta-thalassemia minor is a blood disease caused by a hereditary decrease in beta-globin synthesis, frequently leading to hypochromic microcytic anemia. Formerly called endothelial cell-specific molecule 1, endocan is a proteoglycan released by vascular endothelial cells in many organs. Our aim was to investigate the relationship between the beta-thalassemia minor patients and the healthy control group in terms of serum endocan level. METHODS: The study was performed in a total of 80 subjects. They were divided into two groups, the beta-thalassemia minor group (n=40) and the healthy control group (n=40). Serum endocan levels, age, sex, body mass index value, and tobacco use data of these groups were compared. RESULTS: No statistically significant difference was detected between the two groups in terms of age, sex, and body mass index values (p>0.05). Endocan levels were measured to be 206.85±88.1 pg/mL in the beta-thalassemia minor group and 236.1±162.8 pg/mL in the control group with no significant difference between the groups in terms of serum endocan levels (p>0.05). CONCLUSIONS: In our study, there was no change in endocan level in beta-thalassemia minor. This might be because serum endocan levels are affected by multi-factorial reasons. Serum endocan levels may be altered secondarily to decreased beta-globin chain, increased sympathetic activity due to anemia, or platelet dysfunction induced by oxidative stress in beta-thalassemia minor. Further multicenter studies involving more patients are necessary to demonstrate this.Associação Médica Brasileira2022-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000200147Revista da Associação Médica Brasileira v.68 n.2 2022reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.20210753info:eu-repo/semantics/openAccessKhanmammadov,NijatZorlu,MehmetOzer,Omer FarukKaratoprak,CumaliKıskaç,MuharremÇakırca,Mustafaeng2022-09-01T00:00:00Zoai:scielo:S0104-42302022000200147Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2022-09-01T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false
dc.title.none.fl_str_mv Assessment of serum endocan levels in patients with beta-thalassemia minor
title Assessment of serum endocan levels in patients with beta-thalassemia minor
spellingShingle Assessment of serum endocan levels in patients with beta-thalassemia minor
Khanmammadov,Nijat
Thalassemia
Anemia
Endothelial cells
Proteoglycan
title_short Assessment of serum endocan levels in patients with beta-thalassemia minor
title_full Assessment of serum endocan levels in patients with beta-thalassemia minor
title_fullStr Assessment of serum endocan levels in patients with beta-thalassemia minor
title_full_unstemmed Assessment of serum endocan levels in patients with beta-thalassemia minor
title_sort Assessment of serum endocan levels in patients with beta-thalassemia minor
author Khanmammadov,Nijat
author_facet Khanmammadov,Nijat
Zorlu,Mehmet
Ozer,Omer Faruk
Karatoprak,Cumali
Kıskaç,Muharrem
Çakırca,Mustafa
author_role author
author2 Zorlu,Mehmet
Ozer,Omer Faruk
Karatoprak,Cumali
Kıskaç,Muharrem
Çakırca,Mustafa
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Khanmammadov,Nijat
Zorlu,Mehmet
Ozer,Omer Faruk
Karatoprak,Cumali
Kıskaç,Muharrem
Çakırca,Mustafa
dc.subject.por.fl_str_mv Thalassemia
Anemia
Endothelial cells
Proteoglycan
topic Thalassemia
Anemia
Endothelial cells
Proteoglycan
description SUMMARY OBJECTIVE: Beta-thalassemia minor is a blood disease caused by a hereditary decrease in beta-globin synthesis, frequently leading to hypochromic microcytic anemia. Formerly called endothelial cell-specific molecule 1, endocan is a proteoglycan released by vascular endothelial cells in many organs. Our aim was to investigate the relationship between the beta-thalassemia minor patients and the healthy control group in terms of serum endocan level. METHODS: The study was performed in a total of 80 subjects. They were divided into two groups, the beta-thalassemia minor group (n=40) and the healthy control group (n=40). Serum endocan levels, age, sex, body mass index value, and tobacco use data of these groups were compared. RESULTS: No statistically significant difference was detected between the two groups in terms of age, sex, and body mass index values (p>0.05). Endocan levels were measured to be 206.85±88.1 pg/mL in the beta-thalassemia minor group and 236.1±162.8 pg/mL in the control group with no significant difference between the groups in terms of serum endocan levels (p>0.05). CONCLUSIONS: In our study, there was no change in endocan level in beta-thalassemia minor. This might be because serum endocan levels are affected by multi-factorial reasons. Serum endocan levels may be altered secondarily to decreased beta-globin chain, increased sympathetic activity due to anemia, or platelet dysfunction induced by oxidative stress in beta-thalassemia minor. Further multicenter studies involving more patients are necessary to demonstrate this.
publishDate 2022
dc.date.none.fl_str_mv 2022-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000200147
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000200147
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1806-9282.20210753
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Médica Brasileira
publisher.none.fl_str_mv Associação Médica Brasileira
dc.source.none.fl_str_mv Revista da Associação Médica Brasileira v.68 n.2 2022
reponame:Revista da Associação Médica Brasileira (Online)
instname:Associação Médica Brasileira (AMB)
instacron:AMB
instname_str Associação Médica Brasileira (AMB)
instacron_str AMB
institution AMB
reponame_str Revista da Associação Médica Brasileira (Online)
collection Revista da Associação Médica Brasileira (Online)
repository.name.fl_str_mv Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)
repository.mail.fl_str_mv ||ramb@amb.org.br
_version_ 1754212837319770112